The eVTOL tape still looks like a proof market, not a momentum market. In the latest completed U.S. session, Joby Aviation closed at $8.83 on 56,191,700 shares, Archer Aviation closed at $4.87 on 53,518,300 shares, and EHang Holdings closed at $6.13 on 1,069,200 shares. The connective theme is that each company has a visible talking point, but the market is still separating headlines from evidence while the U.S. 10Y Treasury yield sits at 4.37% and fed funds remain at 3.63%.
For today’s detailed market data, see Joby Daily, Archer Daily, and EHang Daily.
Is Joby becoming a short-squeeze setup, or is the market still focused on dilution and funding risk?
My read is that Joby still looks more like a dilution-and-funding debate than a clean short-squeeze setup, even though the short-interest numbers are large enough to keep the squeeze narrative alive. The most concrete data point in the supplied file set is from Benzinga’s June 28 report, which put JOBY short interest at 15.4%, or about 100.7 million shares. That is a meaningful bearish position, and it matters more because the stock also traded 56,191,700 shares in the latest session. In raw mechanical terms, that is enough liquidity to fuel a sharp move if a real catalyst appears. A large short base in a liquid stock can turn violent very quickly when the information changes.
But the tape does not yet show forced short-covering. Joby closed down 0.45% at $8.83 despite that huge volume, and the stock remains below both its SMA5 of 9.28 and SMA20 of 9.95. RSI14 at 41.78 is also weak rather than explosive. If a squeeze were already underway, I would expect price action to be doing more of the work. Instead, the market absorbed massive volume and still finished lower. That usually points to churn, repositioning, and two-way trading rather than panic from the short side.
The reason shorts are staying involved is also visible in the source set. Benzinga ties the bearish view to continuing dilution and to large operating losses, while the Joby daily report keeps the company in Stage 4 with no fresh FAA-confirmed update in-window. The same daily report says ARKX’s JOBY weight slipped to 2.58% as of June 28, down 0.10 percentage points from the prior reading. That is not a collapse in sponsorship, but it is also not a sign that passive capital is urgently pressing the bull case. The stock is therefore stuck between two realities: enough liquidity and short interest to create upside torque if the story changes, but not enough fresh proof to make that story change today.
The way I see it, that is why the short-squeeze thesis feels premature. Joby is absolutely squeeze-capable in a tactical sense, because the short base is large and the float trades heavily. It is not yet a true squeeze candidate in an informational sense, because the market still has credible reasons to press on capital needs, dilution history, and the absence of a new official milestone. In a 4.37% 10Y environment, investors do not have to pay up for distant aviation cash flows unless the regulatory and commercialization path gets more concrete. My directional lean is cautious. If Joby delivers a hard certification or commercialization surprise, the stock can move fast. Until then, 15.4% short interest looks less like trapped bears and more like a market that still thinks funding risk is the cleaner near-term argument.
Are Archer’s $6 billion order book and $430 million defense push a mispriced catalyst, or just a headline spike?
I think the market is treating Archer’s headline package as interesting but not yet bankable, and the close at $4.87 supports that interpretation. The bullish case is easy to understand. According to the supplied MSN summary, Archer surged as much as 17% intraday after CEO Adam Goldstein’s Fox Business appearance and the defense-partnership angle tied to Anduril. That same coverage said Archer was talking about a $6 billion Midnight order book and roughly $430 million tied to defense expansion. Separately, Simply Wall St reiterated the certification-progress story and argued that the stock still looked materially undervalued on its own framework. On paper, that is exactly the kind of combination that should reset a growth story higher: a large commercial backlog narrative, a defense adjacency, and an FAA-progress angle.
But the market did not hold the move. Archer finished the session up only 1.67%, still below SMA5 at 5.08 and SMA20 at 5.63, with RSI14 at 39.09. That fade matters more than the spike. If investors fully believed those numbers had changed the near-term earnings and funding trajectory, the stock usually would not give back so much of a 17% intraday jump. My view is that the market is drawing a hard line between a compelling narrative and a proved conversion path.
That distinction is especially important because the broader source set still shows a credibility gap. Archer’s daily report says there was no fresh official Archer press release, FAA notice, or SEC filing in the collected window. ARKX also trimmed ACHR to 3.00% as of June 28, down 0.14 percentage points from the prior reading. So while the company is clearly staying inside the investable theme basket, passive support is not expanding into the headline. The market seems willing to listen to the order-book and defense case, but it still wants proof on certification closure, commercialization timing, and how those large figures convert into recognized revenue and durable economics.
I do not think this is a catalyst the market is ignoring. I think it is a catalyst the market is discounting until more of it becomes measurable. That is a meaningful difference. A $6 billion order book sounds enormous, but without clearer delivery cadence and revenue timing, it remains easier to admire than to underwrite. The $430 million defense angle broadens the story and may prove important later, especially if it creates a second demand channel beyond passenger service. Today, though, the data say investors still see Archer as a promising story with weak follow-through rather than a confirmed rerating. My directional lean is neutral to cautiously constructive. The headline set is good enough to keep the upside case alive, but the closing tape says the burden of proof is still on management, not on skeptics.
Is the market refusing to price EHang’s Stage 5 lead until a new operating milestone appears?
Yes. That is the cleanest reading of the tape. EHang still carries the best explicit certification marker in this file set, with the daily report holding EH at Stage 5 and last confirming that status on 2026-06-12. In theory, that should matter a lot in a sector where certification is the main gating variable. In practice, the market is treating that lead as old information until it produces a new commercial or operational proof point. EH closed at $6.13, down 2.85%, below both SMA5 at 6.48 and SMA20 at 7.70, with RSI14 at 34.98. Volume was only 1,069,200 shares, versus more than 56 million for JOBY and more than 53 million for ACHR. That is not what leadership looks like in the tape.
The institutional signal points the same way. ARKX’s holdings page shows ACHR at 3.00% and JOBY at 2.58% as of June 28, while EH does not appear in the visible top holdings list. I do not think that means the market believes EHang’s regulatory position is fake. I think it means investors still do not see enough monetization, scale, or tradability around that lead to reward it with broader allocation. Certification progress can win attention once; sustaining capital support usually requires another layer of evidence.
The missing layer in this run is a fresh company-specific milestone. The EHang daily report explicitly says no new EHang-specific official item surfaced in the 23-hour window, and the article-summary file did not contain a fresh catalyst either. So while Joby is being debated through shorts and dilution, and Archer is being debated through defense, backlog, and commercialization rhetoric, EHang is being asked a different question: what comes after Stage 5? Until the answer includes broader regulatory durability, visible commercial scale, or another hard operating marker, the market keeps treating the lead as necessary but insufficient.
I think that helps explain why the valuation response stays muted even in a sector where certification is supposed to dominate everything else. The market is no longer paying for the milestone alone; it is paying for the conversion of the milestone into cash-flow visibility and institutional comfort. In a higher-rate setting, that distinction becomes even sharper because long-duration stories need active proof to keep attracting capital. My directional lean is cautious on the stock but not dismissive of the underlying lead. EHang still owns an important regulatory talking point. The problem is that the market wants the next proof now, not the last proof repeated. Until a new official operating or commercialization step appears, Stage 5 looks real, but the premium attached to it remains thin.
What to Watch Tomorrow
- First, watch whether Joby gets any official certification or commercialization update strong enough to force shorts to react rather than just sit on the dilution and funding thesis.
- Second, watch whether Archer follows its $6 billion order-book and defense narrative with a formal milestone that ties the headline to certification, deliveries, or revenue timing.
- Third, watch whether EHang produces a new operating or regulatory proof point that moves the story beyond a static Stage 5 label and back into active institutional attention.
This is not financial advice. Do your own research.
Follow @futurewatchlog for daily eVTOL coverage.
Previous insight: https://futurewatchlog.com/2026/06/28/evtol-daily-insight-2026-06-28/